Floatz logo

at9283

Leukemia

Cancer Research UKPhase 1Dormant
CC
40/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
65/ 100

Competitive context

125 Active assets in the Leukemia cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
Inhye Ahn
Phase 3BB
FILGRASTIM
Hospital General de Mexico
Phase 4BB
THIOGUANINE ANHYDROUS
Incyte Corporation
Phase 3BB
ASPARAGINASE
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 3BB
MERCAPTOPURINE ANHYDROUS
Dana-Farber Cancer Institute
Phase 3BB

View all 50 →

Same molecule, other indications

at9283 is also rated in:

childhood neoplasmDormant
CC
Indicative ·
47 / 100
View asset →
plasma cell myelomaDormant
CC
Indicative ·
47 / 100
View asset →
chronic myeloid leukemiaDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →